Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06016465 · ClinicalTrials.gov registry record · Early Phase 1

Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

A Early Phase 1 study of Migraine, sponsored by Texas Tech University Health Sciences Center, El Paso.

Recruiting
Registry status
Early Phase 1
Development phase
84
Enrollment target
1
Study location

NCT06016465 is a Early Phase 1 study of Migraine that is actively recruiting participants, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 84 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06016465, a Early Phase 1 study of Migraine, is actively recruiting participants, sponsored by Texas Tech University Health Sciences Center, El Paso.

RECRUITING
Registry status
Early Phase 1
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

For some patients who come to the emergency department for treatment of a migraine headache, peripheral headache nerve blocks (PHNB) have proven to be an efficient and effective treatment for headache relief. Previous studies have demonstrated that adding steroids as an adjunct treatment to standard migraine treatment can reduce recurrence of headaches in the subsequent few days.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Dexamethasone Oral

Study Locations (1)

Texas

  • University Medical Center of El Paso - El Paso

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2023-09-15
Est. Completion 2026-01-30
Phase Early Phase 1

What the Registry Record Tells You About NCT06016465

The ClinicalTrials.gov registry entry for NCT06016465 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower). The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06016465 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06016465 about?

NCT06016465 is a clinical study titled "Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?". For some patients who come to the emergency department for treatment of a migraine headache, peripheral headache nerve blocks (PHNB) have proven to be an efficient and effective treatment for headache relief. Previous studies have demonstrated that adding steroids as an adjunct treatment to standard...

What is the current status of trial NCT06016465?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 84 participants. The study started on 2023-09-15. Estimated completion is 2026-01-30.

What conditions does trial NCT06016465 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT06016465?

The interventions under investigation include: Placebo (DRUG), Dexamethasone Oral (DRUG).

Who is sponsoring clinical trial NCT06016465?

This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06016465 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.